Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FFAR1 | O14842 | 11/20 | 0.76 |
| ▸ | HTR7 | P34969 | 3/20 | 0.63 |
| ▸ | PTGER1 | P34995 | 2/20 | 0.58 |
| ▸ | PTGER4 | P35408 | 2/20 | 0.58 |
| ▸ | PTGER3 | P43115 | 2/20 | 0.58 |
| ▸ | PTGER2 | P43116 | 2/20 | 0.58 |
| ▸ | FFAR4 | Q5NUL3 | 4/20 | 0.56 |
| ▸ | RXRA | P19793 | 1/20 | 0.53 |
| ▸ | PLA2G10 | O15496 | 1/20 | 0.52 |
| ▸ | PLA2G2A | P14555 | 1/20 | 0.52 |
| ▸ | SLCO1B1 | Q9Y6L6 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30543843 | 0.88 | FFAR1 (0.61) | FFAR1HTR7PTGER1PTGER4PTGER3 | |
| SCHEMBL1747222 | 0.87 | FFAR1 (1.00) | FFAR1FFAR4 | |
| SCHEMBL2587121 | 0.86 | SELL (0.62) | FFAR1HTR7PTGER1PTGER4PTGER3 | |
| SCHEMBL1672424 | 0.85 | FFAR1 (0.58) | FFAR1FFAR4 | |
| SCHEMBL9228039 | 0.84 | FFAR1 (0.59) | FFAR1FFAR4 | |
| SCHEMBL3677264 | 0.84 | FFAR1 (0.66) | FFAR1FFAR4RXRA | |
| SCHEMBL22398944 | 0.84 | HTR7 (0.71) | FFAR1HTR7 | |
| SCHEMBL6490922 | 0.83 | FFAR1 (0.58) | FFAR1FFAR4RXRA | |
| SCHEMBL7725124 | 0.83 | FFAR1 (0.58) | FFAR1FFAR4RXRA | |
| SCHEMBL9230739 | 0.82 | HTR7 (0.69) | FFAR1HTR7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7812038-B2 | Carboxylic acid derivatives that inhibit the binding of integrins to their receptors | ENCYSIVE PHARMACEUTICALS, INC. (US) | 2010-10-12 | — | — | US | disclosed |
| US-20060276476-A1 | Carboxylic acid derivatives that inhibit the binding of integrins to their receptors | BIEDIGER RONALD J | 2006-12-07 | — | — | US | disclosed |
| US-6972296-B2 | Carboxylic acid derivatives that inhibit the binding of integrins to their receptors | ENCYSIVE PHARMACEUTICALS INC. (US) | 2005-12-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060276476-A1 | Carboxylic acid derivatives that inhibit the binding of integrins to their receptors | VCAM1, ICAM1, ITGA1 | FFAR1 74/4885HTR7 2609/4885PTGER1 999/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.